Order Article Reprints

Masloh S, Chevrel A, Culot M, Perrocheau A, Kalia YN, Frehel S, Gaussin R, Gosselet F, Huet S, Zeisser Labouebe M, et al. Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Pharmaceutics. 2024; 16(1):116. https://doi.org/10.3390/pharmaceutics16010116

Masloh, Solene, Anne Chevrel, Maxime Culot, Anaëlle Perrocheau, Yogeshvar N. Kalia, Samuel Frehel, Rémi Gaussin, Fabien Gosselet, Simon Huet, Magali Zeisser Labouebe, and et al. 2024. "Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model" Pharmaceutics 16, no. 1: 116. https://doi.org/10.3390/pharmaceutics16010116

Masloh, S., Chevrel, A., Culot, M., Perrocheau, A., Kalia, Y. N., Frehel, S., Gaussin, R., Gosselet, F., Huet, S., Zeisser Labouebe, M., & Scapozza, L. (2024). Enhancing Oral Delivery of Biologics: A Non-Competitive and Cross-Reactive Anti-Leptin Receptor Nanofitin Demonstrates a Gut-Crossing Capacity in an Ex Vivo Porcine Intestinal Model. Pharmaceutics, 16(1), 116. https://doi.org/10.3390/pharmaceutics16010116